连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察

目的:评价中药连花清咳治疗新型冠状病毒肺炎的临床有效性和安全性。方法:采用随机对照临床研究方法,纳入依据《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》诊断为新型冠状病毒肺炎且存在咳嗽症状的18岁以上患者。采用随机数字表法分为对照组和观察组,分别给予常规治疗或加服连花清咳颗粒(1袋/次,3次/d)治疗14 d。主要评价指标为咳嗽症状消失率。结果:57例受试者纳入本研究,其中对照组25例,观察组32例。观察组咳嗽症状消失率为90.6%(29/32),明显高于对照组的64.0%(16/25)(P<0.05),观察组的咳嗽治疗起效时间明显早于对照组(P<0.05),咳嗽症状持续时间明显短于对照组(P<0.05)。观察组的咳痰症状消失率为94.7%(18/19),明显高于对照组的57.1%(8/14)(P<0.05),且观察组的咳痰治疗起效时间明显早于对照组(P<0.05),咳痰症状持续时间明显短于对照组(P<0.05)。观察组的CT好转率为96.9%(31/32),明显高于对照组的72.0%(18/25)(P<0.05)。经过治疗后,两组受试者的氧合指数有不同程度升高,观察组的氧合指数升高率(52.7%)明显高于对照组(23.9%)(P<0.05)。观察组发热、乏力、咽干、咽痛症状消失率与对照组比较,差异无统计学意义,但显示出在常规治疗基础上加用连花清咳有较好的改善趋势。结论:在常规治疗基础上加用连花清咳可以显著改善新冠肺炎患者的咳嗽、咳痰症状,促进咳嗽、咳痰症状改善,缩短咳嗽、咳痰症状持续时间,减轻肺部病变,改善呼吸功能,对发热、乏力、咽干、咽痛症状也显示出良好改善趋势。

Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19

Objective:To evaluate the clinical efficacy and safety of traditional Chinese medicine Lianhua Qingke granule(LH granule)in the treatment of coronavirus disease 2019(COVID-19).Method:A randomized controlled method was used in this clinical study.The subjects were confirmed COVID-19 patients over 18 years old with cough symptoms,and the diagnosis is based on Diagnosis and Treatment Protocol for COVID-19(Trial Version 6).The subjects were randomized to usual treatment(control group)or in combination with LH granule(1 bag,thrice daily)for 14 days.The primary endpoint was the rate of cough recovery.Result:57 subjects were included in this study,including 25 in the control group and 32 in the observation group.The recovery rate of cough in observation group was 90.6%(29/32),which was significantly higher than 64.0%(16/25)in the control group(P<0.05).The effective time of cough treatment was significantly earlier than that of the control group(P<0.05),the median time to cough recovery was markedly shorter in treatment group(P<0.05).The recovery rate of expectoration in observation group was 94.7%(18/19),which was significantly higher than 57.1%(8/14)in the control group(P<0.05).The effective time of expectoration treatment was significantly earlier than that of the control group(P<0.05),and the median time to expectoration recovery was markedly shorter in treatment group(P<0.05).The improvement rate of CT in the observation group was 96.9%(31/32),which was significantly higher than 72%(18/25)in the control group(P<0.05).After treatment,the oxygenation index of the two groups increased in varying degrees,and the increase rate of the observation group was significantly higher than that of the control group(P<0.05).There was no significant difference in the recovery rate of fever,fatigue,dry pharynx and sore throat between the observation group and the control group,and it showed that LH had a better improvement trend on the basis of usual treatment.Conclusion:On the basis of routine treatment,LH can significantly improve the symptoms of cough and expectoration of COVID-19 patients,shorten the duration of cough and expectoration symptoms,reduce lung pathological damage,improve respiratory function,and improve the symptoms of fever,fatigue,dry pharynx and sore throat.